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It is now clear that the outcome of an inflammatory process caused by infections depends 
on the balance of responses by several components of the immune system. Of partic-
ular relevance is the interplay between regulatory T cells (Tregs) and CD4+ T cells that 
produce IL-17 (Th17 cells) during immunoinflammatory events. In addition to discussing 
studies done in mice to highlight some unresolved issues in the biology of these cells, 
we emphasize the need to include outbred animals and humans in analyses. Achieving 
a balance between Treg and Th17 cells responses represents a powerful approach to 
control events during immunity and immunopathology.
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iNTRODUCTiON
The realization that CD4+ T cells could be differentiated in two phenotypically separate lineages, 
Th1 cells that predominantly produce IFN-γ and IL-2 while Th2 cells produce IL-4 and IL-10, was 
elucidated by Mosmann et al. (1). The idea caught on because these cell types cross-regulated each 
other and this phenomenon helped in explaining many observations in inflammatory and infectious 
diseases. Subsequently, several additional subtypes of CD4+ T cells were discovered based on the 
transcription factor expressed, their cytokine profile and functions (2, 3). Of particular relevance 
was the discovery that some CD4+ T cells play a regulatory role and helped to constrain the effector 
function of other cell types. We currently recognize at least four CD4+ T cell subsets which largely 
play an effector function (Th1, Th2, Th9, and Th17) and another subset T follicular helper cell (TFH) 
which plays a major role during immune induction (4). This review focuses largely on the cross play 
between regulatory T cells (Tregs) and Th17 cells since these two subsets often subserve opposite 
roles during inflammatory processes. Th17 cells are recognized as one of the predominant proinflam-
matory cell types and produce IL-17 to help attract other innate immune cells such as macrophages 
and neutrophils to further aggravate chronic inflammation. The transcription factor RAR-related 
orphan receptor (ROR)-γt regulates the speciation program of Th17 cells. Tregs on the other hand act 
to regulate the differentiation and activity of Th17 cells. In fact, several lines of evidence demonstrate 
that Treg and Th17 cells exhibit some key shared differentiation pathways (Figure 1). Thus, both cell 
types require TGF-β and IL-2 for their differentiation and are predominantly present in the gut to 
maintain homeostasis (5). Both Treg and Th17 cells exhibit specificity toward commensal-derived 
antigens or self-antigens and their speciation transcriptional program shows direct interaction (5). 
Of the two major classes of antigen-presenting cells (APCs) in the gut, dendritic cells (DCs) are 
known to promote Th17 cell responses while macrophages promote Treg responses (6). Treg and 
Th17  cells were shown to predominantly maintain gut homeostasis but their interplay in other 
FigURe 1 | Differentiation of T regulatory cells (Tregs) and Th17 to 
effect immunity and immunopathology during infections. Antigen-
presenting cells (APCs) either by direct infection or by exogenously taking up 
antigens process polypeptides intracellularly to generate peptides. These 
peptides are loaded onto class II MHC molecules and presented on their 
surface to activate naïve Th cells. Depending upon the affinity of TCR to 
recognize processed peptides and the microenvironment in which such 
interactions take place, Th cells are polarized into pTreg and Th17 cells to 
maintain homeostasis. Treg and Th17 cells can also transdifferentiate 
depending on intrinsic as well as some extrinsic factors such as local 
concentration of TGF-β. Predominant products of Treg include IL-10, IL-35, 
and TGF-β in addition to membrane-expressed molecules while Th17 cells 
secrete IL-17, IL-21, IL-22, and other cytokines. Tregs cause 
immunoregulation while Th17 serve as proinflammatory cells during disease 
progression. Treg and Th17 leads to differential outcome ranging from 
dominant regulatory to stimulatory activity while a fine balance ensures 
homeostasis.
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diseases that include those caused by infections is beginning to 
be appreciated.
The idea that T  cells could suppress the function of other 
cells was popularized by Gershon and Kondo (7). The cells were 
called suppressor cells, but since there were no reliable means 
of identifying them, they soon fell into disrepute. Resurrection 
and respectability for Treg came some two decades later by the 
work performed by the Sakaguchi et al. and Suri-Payer et al. who 
had discovered a reliable way of distinguishing Treg from other 
cell types and also demonstrated their regulatory effects (8–10). 
Sakaguchi et al. and Thornton and Shevach demonstrated that 
5–10% of T helper (Th) cells that expressed the high affinity 
IL-2 receptor alpha (α) chain (CD25) were present in naïve 
mice and were able to suppress the proliferation of those cells 
that did not similarly express this molecule (9, 11). The idea of 
Treg’s existence helped in explaining many unsolved mysteries 
in immunobiology such as how tolerance is maintained and 
the variable outcome of autoimmune and infectious diseases is 
effected (12–14). The canonical transcription factor Fork head 
box protein 3 (Foxp3), responsible for controlling the function 
of Treg and acting as their identifier, was discovered in 2001 
(15–17). Whereas Foxp3+ Tregs are perhaps the most prominent 
regulatory cells, other cell types have been observed to mediate 
regulatory effects alongside or alternatively to Foxp3+ Treg. 
These many alternative regulators include Tr1 cells, Th3 cells, 
CD8+ Treg, double negative CD3+ T  cells, gamma delta (γδ) 
T cells, natural killer T cells, regulatory B cells, myeloid-derived 
suppressor cells, and perhaps others.
A great majority of our understanding of how the immune sys-
tem works comes from studies performed in inbred mice housed 
in controlled environment. Our ultimate objective, however, is 
to understand the workings of the immune system and to apply 
the wisdom to manipulate the outcome of events in humans and 
other animals. There is still a gap in our knowledge regarding 
what happens in humans and outbred non-rodents and this issue 
is elaborated in this review. We also discuss unresolved issues 
in the biology as well as pathophysiology of Treg and Th17 cells 
during infectious diseases.
BiOLOgY OF TReg AND Th17 CeLLS
The expression of the transcription factors Foxp3 and ROR-γt 
defines Treg and Th17  cells, respectively. Foxp3 is critically 
involved in the differentiation and function of Treg. Foxp3 
does so by directly binding to DNA to be transcribed and in so 
doing regulates the transcription of more than thousand genes 
many of which are involved in T  cell activation. Some of the 
Treg-specific genes directly targeted by Foxp3 are Il2ra (CD25), 
Tnfrsf18 (GITR), Nrp1 (neuropillin-1), and Ccr4 among others 
(18–20). Foxp3 could also influence gene expression indirectly 
by recruiting epigenetic modifiers such as histone deacetylases 
(HDAC1, 2, and 3) in the complex (21). Many genes that include 
Il2 are downregulated by HDACs activity. As newer mechanistic 
insights are emerging, clearly there is need of more studies to 
better define the role of Foxp3 in programming Treg and in fact 
different functions could be attributed to its different domains. 
Similarly, Foxp3 regulates the expression of some chemokine 
receptors suggesting that it may also control the homing of Treg. 
The latter effect has not received much attention and needs to be 
understood in greater detail. This is because immunosuppression 
at inflammatory sites is one of the most desirable outcomes of 
cell-based immunotherapies.
Tregs are broadly divided into thymically derived regulatory 
T  cells (tTregs) and those that are induced in the periphery 
(pTregs). pTregs are usually more plastic than tTregs (22). Nrp1 
may act as the distinguishing marker between tTreg (+) and pTreg 
(−) (23–25). Tregs in the thymus develop after 3  days of birth 
and a thymectomy at 3  days of birth abrogates Treg responses 
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leading to multiorgan autoimmune inflammatory diseases (26). 
However, some Treg that specifically home to select lymphoid 
organs can be detected in 3-day-old thymectomized mice (27). 
Therefore, it could be that the kinetics of Treg generation in the 
thymus is also linked to their differential homing pattern. As and 
when growing animals are exposed to different environmental 
conditions that include feed and habitation, the homing proper-
ties, functionality, and repertoire of Treg may be refined further 
to maintain homeostasis at different locations.
For the induction of T cell responses that include Treg, three 
signals comprising MHC–peptide–TCR, engagement of co-stim-
ulatory/inhibitory molecule, and cytokines in milieu are required 
(28, 29). Issues such as the strength and the nature of inducing 
signals and the subsequent formation of either plastic or stable 
Treg are beginning to be investigated (30). Low to intermediate 
affinity interactions between the TCR expressed by developing 
T  cells and peptides–MHC class II complexes in thymus are 
considered as one of the critical drivers of Treg differentiation 
(28). Contrary to what was considered as a paradigm that both 
α and β chains of the TCR are involved in peptide binding (31), 
a recent study demonstrated that only the β chain of TCR along 
with its framework regions contributed to peptide binding in 
Tr1 cells and thereby making it a very low affinity interaction 
(32, 33). However, one wonders how such a weakly interacting 
TCR ensures survivability of T cells during the thymic selection 
process. Whether or not TCRs of different types of Treg also 
display a similar orientation and affinity remains unexplored.
The affinity with which TCRs of Th17 cells recognize pep-
tides has not been extensively explored. Only a few studies 
have demonstrated that TCRs of Th17 cells might exhibit a low 
affinity (34). High affinity interactions in fact might be counter-
productive for gut health, a site so heavily infested by microbes. 
Thus, in healthy individuals a unique tripartite interaction 
among gut microbiota, Treg, and Th17  cells may be required 
to maintain gut homeostasis (35). Conceivably, Th17 cells act 
to control the excessive growth of microbes in the gut while 
Tregs regulate Th17 cell responses. Whether Th17 cells exhibit 
differential TCR specificity or affinity toward antigens and how 
it affects their pathogenicity is worth investigating and could 
indeed help identify Th17 cell subsets with different functions. 
Some studies have supported a similar idea that Th17  cells 
could indeed exist in different subtypes (36–38). Accordingly, a 
local intracellular concentration of saturated fatty acids (SFA) 
compared to polyunsaturated fatty acids (PUFA) favored more 
pathogenic Th17 cell formation (38). Differential accumulation 
of SFA or PUFA and their binding to intracellularly expressed 
CD5L led to the generation of Th17 exhibiting differential 
pathogenicity (38).
The stimulating antigens for Treg and perhaps for Th17 cells 
could also be generated during an ongoing inflammatory response 
caused by autoimmune diseases or infections. To support this 
notion, a few studies have demonstrated that Tregs isolated from 
draining LNs are more active and better suppressors as compared 
to those isolated from distal LNs (39–42). In draining LNs, 
APCs home from local sites and predominantly sample antigens 
released from these areas. This provides ample stimulation for 
Treg to remain better suppressors.
TGF-β is a critical cytokine required at least in vitro for induc-
ing the regulatory phenotype in T cells. Depending on the con-
centration, context, and condition, TGF-β helps skew responses 
toward Treg or Th17 cells (43, 44). Thus, a greater concentration 
of TGF-β may be conducive for a Treg response while a lower 
concentration particularly in the presence of other inflammatory 
cytokines such as IL-6 and IL-21 could preferentially promote 
Th17 responses (45). In fact, some pathogens either encode for 
the homologs of TGF-β or help activate latent TGF-β and this 
may be responsible for differential proinflammatory or regulatory 
responses (46). Whether or not TGF-β is critical for Treg genera-
tion in the thymic environment was investigated in the absence 
of TGF-β signaling using complete knockout or T  cell specific 
TGFβRII knock out mice (47–49). These studies revealed that an 
absence of TGF-β signaling only affected the peripheral pool of 
Treg and not their thymic generation (47). It could also suggest 
that Treg that develop in the thymus halt their proliferation and 
remain quiescent until they home to the periphery. The reduced 
proliferation of Treg in the thymus could be the consequence of 
limited antigen availability and the presence of abundant TGF-β, 
both of which could serve to induce slow proliferation of Treg 
(48). The thymic microenvironment could indeed provide copi-
ous amount of TGF-β for Treg differentiation or maintenance 
because of an ongoing process of apoptosis and disposal of 
such cells by phagocytic activity of DCs and macrophages (49). 
Another signal that has been implicated in Treg generation is 
retinoic acid, a metabolite of vitamin A (50). The expression 
of TGF-β and retinoic acid has also been demonstrated in the 
thymus supporting the notion that these induction pathways 
either alone or cooperatively could help thymic Treg generation 
(51–53).
IL-2 signaling is critically involved in Treg as well as Th17 cell 
differentiation. IL-2 is consumed preferentially by Treg since they 
express high affinity IL-2 receptors (54). IL-2 also acts to stabilize 
Foxp3 induced by TGF-β (30, 55). Treg are supposed to dampen 
inflammation where a mix of both pro- and anti-inflammatory 
cytokines constitutes the microenvironment. Therefore, the func-
tionality of Treg needs to be evaluated in the presence of relative 
abundance of different cytokines. TGF-β and IL-2, if present in an 
environment along with other proinflammatory cytokines such 
as IL-1β, IL-6, IL-21, or IL-23, facilitate Th17 differentiation at 
the expense of Treg (56). It is worth investigating how ROR-γt in 
Th17 cells actually promotes their programming. Thus, whether 
or not the transcription factor ROR-γt in Th17 cells actually binds 
in the promoter region of IL-17 to modulate its expression has 
not been shown experimentally. However, a putative binding site 
of ROR- γt in IL-17 promoter has been predicted (57). Similarly, 
any naturally existing endogenous ligands for ROR-γt is yet to be 
identified. The induction kinetics of such ligands during infection 
could provide better insights into the differentiation of Th17 cells 
during an ongoing immune response and provide potential tar-
gets to block a pathogenic response. One such example is binding 
of an artificial ligand digoxin to ROR-γt which acts to diminish 
IL-17 production (58). The factors shown to favor and antago-
nize Treg and Th17 cells in different species are summarized in 
Table  1. In a subsequent section, we highlight technological 
advances that facilitated Treg or Th17 cell response investigations 
TABLe 1 | A summary of positive and negative regulators of regulatory 
T cell (Treg) and Th17 cell response in different species.
Species Tregs CD4+ T cells that produce 
iL-17
Promoting 
factors
inhibiting 
factors
Promoting 
factors
inhibiting 
factors
Mouse IL-2 IL-6 IL-6 TGF-β (high 
concentration)
TGF-β TNF-α TGF-β (low 
concentration)
IL-2
IL-10 IL-1β IL-21 IL-4
Lower affinity of 
TCR
IL-23 IL-12
Saturated fatty 
acids
IFN-γ
IL-1β Polyunsaturated 
fatty acids
Estradiol
Human Antigen or 
mitogen
IL-6 IL-6 TGF-β
IL-2 IL-21 TGF-β (low 
concentrated)
IL-4
TGF-β IL-23 IL-21 IL-12
IL-17 IL-23 IFN-γ
TNF-α
IL-1β
RANTES
Canine 
(dogs)
Con-A IL-6 IL-6 TGF-β
IL-2 IL-1β IL-1β
TGF-β TFG-β
IL-10
Feline 
(cats)
Mitogens IL-6 IL-1β TGF-β
LPS and flagellin IL-1β IL-6 IL-10
IL-2 TGF-β
IL-21
Bovine Antigen or 
mitogens along 
with IL-10, TGF-β
IL-6 IL-23 Progesterone, 
IFN-γ
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as well as their interplay and also make some comments about 
their potential therapeutic value.
HOw DO we STUDY THe FUNCTiON AND 
PHeNOTYPe OF TReg AND Th17 CeLLS?
A summary of the key technological advancements that has 
facilitated studies involving phenotype and function of Treg and 
Th17 cells is provided in Figure 2. One of the initial identifiers 
of Treg in naïve mice was surface expression of CD25 (IL-2R α 
chain) and this served as a marker to facilitate their isolation and 
characterization (10). The discovery of the bona fide transcription 
factor Foxp3 advanced the field since it is distinctive of Treg and 
separates them from non-Treg during ongoing infections. Foxp3 
not only confers Treg with their regulatory function but also is 
used for monitoring Treg responses during disease progression 
to serve as a prognostic biomarker (15, 16, 59–62). As Foxp3 is 
expressed intracellulary, its detection requires cells to be per-
meabilized, which renders them dysfunctional, and hence limits 
utility. The issue was addressed in inbred mice by Bettelli et al. and 
Fontenot et al. who constructed a Foxp3-GFP knock-in mouse so 
that live cells could be recovered based on GFP positivity (63, 64). 
This model also allowed studying migration and localization of 
Treg during infections (65–67). Other transgenic mouse models 
such as Foxp3-diphtheria toxin receptor (DTR) also helped 
advance our understanding of the function and pathophysiology 
of Treg especially during ongoing infections and immune activa-
tion. The DTR is not naturally present in mice and, therefore, a 
selective depletion of Treg could be achieved by injecting minimal 
dose of diphtheria toxin (13, 66, 68, 69). Many studies employed 
this model to study the role of Treg during different stages of an 
ongoing infection or autoimmune disease (66, 70).
A confounding problem, however, complicated matters since 
it was realized that Treg might lose their expression of Foxp3 as 
well as their regulatory function. Moreover, such cells could even 
take on the function of effector T cells (4). This phenomenon is 
usually referred to as plasticity or the transdifferentiation. This 
can be investigated with the availability of so-called fate mapping 
mice (77, 78). Such animals are constructed in a way that desirable 
gene products such as Foxp3 or IL-17 are driving Cre recombi-
nase. Crossing these animals with reporter floxed mice having a 
transgene for fluorescent protein generated fate-mapping mice to 
address plasticity issues during infections and other inflammatory 
situations (77, 79). Whether or not proinflammatory cells produc-
ing IL-17 could also become regulatory at a later time, triple fate 
mapping mice have now been created (77). Using these animals, 
it was demonstrated that Th17 cells could transdifferentiate into 
Tr1 cells in a model of parasite induced inflammatory disease 
(77). Thus, fate-mapping mice have become a valuable model to 
follow the functional changes of T cell subsets in different situa-
tions. The method of generation such as inducible vs constitutive 
expression of transgene/reporter, number of copies inserted, and 
the expression of products under non-endogenous promoters 
could, however, impact on the overall utility of such animal 
models (80). Whether or not Treg plasticity occurs in humans has 
been difficult to quantify and co-staining for different markers 
followed by multicolor flow cytometry represents one surrogate 
way to measure it. In order to generate phenotypically stable 
regulatory T cells, approaches that modify epigenetic architecture 
are used. For example, epigenetic modifiers such as HDACs or 
DNA methyltransferases (DNMTs) inhibitors are used. The use 
of azacytidine that inhibits DNMTs activity ameliorated herpes 
simplex virus 1 (HSV-1) induced ocular inflammatory lesion and 
enhanced Treg responses (81).
In order to gain insights into the functioning of Treg or 
Teffectors in lymphoid organs or in inflammatory tissues, cells 
need to be visualized in vivo. This could be achieved using two 
photon intravital microscopy but its accessibility is limited 
(82, 83). Many observations obtained using inbred strains may 
not translate to outbred populations for reasons such as the rep-
resentation of limited MHC polymorphism in former animals. 
In addition, spontaneous exposures of feral animals to multiple 
antigens as compared to those that are housed in clean facilities 
may also yield confounding conclusions. That a dirty environ-
ment can make a difference is being emphasized and may include 
differential migration pattern of immune cells as was shown for 
CD8+ T cells (84, 85). This led to differential outcome during a 
subsequent viral infection (84). There is no reason to believe that 
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such a situation would not exist for Th subsets and other types 
of infections.
One model that could be valuable to address such issues 
is the zebrafish (Danio rerio) (86). The model could be par-
ticularly valuable to study cellular interactions due to its ana-
tomical visual transparency. For investigating Treg and Th17 
responses in zebrafish, the genes encoding for transcription 
factors Foxp3 and ROR-γt have been cloned successfully (87). 
The immune cells and molecules known to exist in vertebrates 
critical for adaptive immunity are also present in zebrafish 
(88). Procedures such as transgenesis, nuclear reprogramming, 
and gene function disruption can be performed with ease in 
these animals as compared to mice (89–92). Therefore, rather 
than demonstrating immunological events with select few 
lines, multiple lines of zebrafish can be generated and used 
(93, 94). Moreover, the zebrafish is an excellent model for trac-
ing some infectious diseases such as tuberculosis. The granu-
loma formed by mycobacterial infection in zebrafish exhibits 
similar histological and pathological features as are evident in 
Mtb infected human granuloma lesions (95, 96). The zebrafish 
model could surely empower immunologists to visualize the 
cross regulation of Treg and Th17 cells in pathophysiology of 
diseases.
The functionality of Treg and Th17 cells can be measured by 
various in vitro assays and in vivo adoptive transfer approaches. 
In vitro functional assays include isolating and co-culturing Treg 
with identifiable non-Treg to measure the functionality (11, 97). 
Whether or not suppressive activity is contact dependent can be 
established using trans well assays (11). The responding cells used 
for suppressive assays can either be stimulated in a polyclonal 
manner or by antigen pulsed APCs (98).
COMPARiSON OF TReg AND Th17 
ReSPONSe iN HUMANS, RODeNTS, AND 
NON-RODeNT ANiMALS
Although there are considerable similarities in the function and 
phenotype of Treg as well as Th17 cells isolated from mice and 
humans, differences are also evident. Isoforms of Foxp3 that lack 
exon 2 or exon 7 exist in human, but not in mice suggesting that 
the differentiation pathways for Treg in humans and mice may 
differ (99). Stimulated CD4+CD25− T cells in the presence of IL-2 
and TGF-β, express Foxp3 and IL-2 acts to stabilize the expres-
sion (30). In the absence of TGF-β, Foxp3 could be expressed 
transiently in stimulated Foxp3− T cells isolated from humans and 
to a lesser extent in mice but human cells express latent TGF-β on 
their surface (100–102). Reactive oxygen species are abundantly 
present during the initial stages of inflammation and can activate 
latent TGF-β to make it available for further differentiation into 
either Treg or Th17 cells. The stages of human Treg generation 
when TGF-β and IL-2 are critically involved are not yet clearly 
identified and most studies have concluded that these cytokines 
dominantly help stabilize Foxp3 expression (49). Varying degrees 
of epigenetic changes in the Foxp3 locus of human and mouse 
Treg have been observed (103, 104). Thus, the Foxp3 locus in 
humans is methylated to a greater extent as compared to that in 
mice suggesting human Treg take longer to adopt a phenotype 
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similar to that of mouse Treg (30). The identification markers 
used for distinguishing human and mouse Treg also display dis-
cordance. Thus, even Foxp3 cannot be used for unambiguously 
defining Treg in humans, unlike in mice (105). Cells expressing 
sustained Foxp3 expression, however, are considered as suppres-
sive cells. The recently described marker Nrp1 that distinguishes 
mouse tTreg from pTreg does not faithfully identify one subset or 
the other in humans (106).
IL-6 and TGF-β play a non-redundant role in the generation of 
mouse Th17, but this may not be true for human Th17 cell genera-
tion (107). IL-1β, TNF-α, and IL-23 are all effective inducers of 
ROR-γt in differentiating human Th17 cells (108). TGF-β may be 
dispensable for Th17 cell generation in humans but not in mice 
(101). The requirement of factors for differentiation of human 
Th17  cells, however, needs to be cautiously interpreted. Thus, 
most studies focusing on differentiation of human Th17 cells were 
performed using peripheral blood cells, and donors are expected 
to have an exposure to one or more antigens. Therefore, the start-
ing population may not be naïve. Cells are more likely to be naïve 
when isolated from cord blood and for such cells to differentiate 
into Th17, TGF-β seems to be critically involved (107). Therefore, 
differentiation and transdifferentiation of human Th cells need to 
be fully understood for both naïve and committed cells in order 
to manipulate Th17 cell responses.
Regulatory T cells and to a lesser extent Th17 cells have been 
described to exist in most non-rodent animals as well. However, 
as is described for humans and mice, a mutation in Foxp3 and any 
subsequent phenotypic effect has not been described in other ani-
mals. This could be because of the rarity of such genetic disorders. 
Anti-human or mouse Foxp3 monoclonal antibodies that cross-
react with xenogeneic Foxp3 molecule are used for immunophe-
notyping Treg in other animal species. Various domains of Foxp3 
are conserved across different species and hence show appreciable 
cross reactivity (109). Foxp3 specific monoclonal antibodies were 
produced for some non-rodents such as cats and bovines to detect 
and measure Treg responses (110–112). In cats, an alternative 
splice variant of Foxp3 lacking exon 2 also exists, an observation 
similarly recorded for human Foxp3 (99). Surprisingly, when wild 
type and the variant lacking in exon 2 were expressed in a cell, the 
suppressive activity was enhanced, as compared a single version 
expressing cells suggesting a critical role of exon 2 in activity of 
Treg (111). Cytokines shown to promote Th17 responses in cats 
are IL-1β, IL-6, TGF-β, and IL-21 (113). Foxp3+ Treg have been 
demonstrated in animals that include pigs, cows, sheep, goat, 
horses, baboon, macaque, chimpanzee, harbor seals, and walrus 
(109). The Foxp3 expression could be induced in CD4+ as well as 
CD8+ T cells isolated from lymph node of healthy dogs that were 
stimulated with Con-A (114). A subset of cells that express Foxp3 
at intermediate level, but not Foxp3 high cells, also expressed IFN-
γ suggesting a plastic nature of such stimulated Treg as well as 
their tendency to acquire an effector phenotype (115). This could 
also means that those cells that express optimal level of Foxp3 are 
more stable as compared to those expressing it to a lower level 
and the latter cells are not fully committed to Treg phenotype. 
CD4+ T  cells isolated from PBMCs could be efficiently polar-
ized into Th17 cells using a poly-specific stimulator con-A and 
a combination of cytokines that include IL-6, IL-1β, and TGF-β 
(116). Foxp3+ Tregs in other species were also described. In fact, 
suppressor cells in domestic animals were described even before 
CD25+CD4+ T cells description in mice. In most of these studies, 
PBMCs stimulated with con-A for a few days acquired suppressive 
activity toward autologous and allogeneic blood cells (117), but 
phenotypic markers of these suppressor cells were not described. 
More recently, Foxp3 was detected not only in bovines αβ-T cells 
but also in a small proportion of γδ-T cells that were stimulated 
with Con-A (118, 119). In fact, a recent report suggested that in 
ruminants that includes bovines, γδ-T cells predominantly play 
a regulatory role by producing copious amounts of IL-10 and the 
contribution of CD4+CD25+ Foxp3+ T cells as regulatory cells is 
minimal (120). In small ruminants that include sheep and goats, 
Foxp3 expression was not only limited to CD4+ T cells, but was 
also detectable in other cells such as CD4+CD8+ T  cells, CD4-
CD8+ T cells, as well as double negative CD3+ T cells (109). The 
proportion of non-CD4+ T cells showing Foxp3 expression was 
variable however. The recorded variation in Treg responses could 
be attributed to a lack of appropriate reagents, pathophysiologi-
cal condition of animals, and accessibility to tissues samples for 
analysis. Animals that are also used for meat purpose, the analyses 
could be performed using peripheral blood as well as accessing 
lymphoid organs from slaughtered animals.
In summary, Treg and Th17 cells are likely to be present in 
most vertebrate species as these cells are thought to have co-
evolved (5). The contribution of Th17  cells and the cytokine 
IL-17 in the pathogenesis of some infectious diseases in some of 
the non-rodent animals has been described (116, 121). However, 
most of these studies are observational, and cells were isolated 
from peripheral blood samples only.
iNTeRCONveRSiON OF TReg AND Th17 
CeLLS
Does plasticity of Th subsets confer any advantage to the host? 
The answer probably is in the affirmative. Thus, thymic regression 
with age limits T cell precursor frequency and the interconverting 
ability of different Th subsets could provide a facility for the gen-
eration of an appropriate helper T cell response required for an 
efficient adaptive immunity. The cytokines present in the milieu 
dictate the phenotype of cell upon differentiation, which is well 
appreciated (122). Functional alteration can include a loss of a 
useful function, gain of an undesirable activity, or a change in cell 
location from the site where they normally function. Naïve non-
Treg (CD4+Foxp3-) are converted into Treg (CD4+Foxp3+) when 
stimulated in the presence of IL-2 and TGF-β (11). Similarly, the 
forced expression of Foxp3 converted conventional T cells into 
Treg that exhibited a suppressive activity (59). Treg may lose 
expression of Foxp3 but may not necessarily undergo functional 
changes (123). Alteration in a cell location is usually explained by 
differential expression of homing molecules and this relocation 
can also explain functional changes in some instances (40, 42). 
Relocation effects may help explain changes in Treg activity dur-
ing different phases of an inflammatory response. In fact, during 
an acute inflammatory response, the number of Foxp3+ Treg in 
draining lymph node is reduced dramatically while their number 
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increased in distal lymph nodes. This could mean that Treg 
prefer to stay in a non-inflammatory environment conceivably 
by modulating their homing receptors. This may also mean that 
Treg are more efficient in regulating responses that are milder in 
nature. Alternatively, those cells that reside in the most severe 
inflammatory environments and still retain the phenotype are 
more resilient and less likely to become non-Treg. All these issues 
have yet to be addressed adequately.
Among factors responsible for conferring stability and limit-
ing, plasticity is the continuous availability of cytokines such as 
IL-2 (124). Treg that are deprived of IL-2 and potentially other 
cytokines are more inclined to change their phenotype (125). At 
a molecular level, this outcome can be explained in terms of epi-
genetic alterations in the conserved non-coding sequences (CNS) 
of Foxp3 gene (126). Some have advocated that the subsets of Treg 
that are more plastic are those at an intermediate stage of their dif-
ferentiation (122, 126). Such cells may eventually fail to establish 
their complete epigenetic architecture, an effect that can be influ-
enced by the microenvironment (122). One of the most studied 
epigenetic modifications that is known to influence the stability 
of Treg is methylation of CpG islands in the CNS2 of Foxp3 gene, 
also known as Treg-specific demethylated region (TSDR) (126). 
Thus, those Treg that have a hypomethylated Foxp3 TSDR are 
more stable as compared to those whose TSDR is hypermeth-
ylated (125, 126). This also relates to the expression of Foxp3 
and its ability to promote expression of Treg associated genes. 
Accordingly, the activity of DNA methyl transferases in such cells 
may decide whether phenotypically stable cells will be generated 
or not. Nrp1 a molecules differentially expressed by tTreg is also 
involved in stabilization of Foxp3 expression. Signaling induced by 
ligation of Nrp1 with semaphorin-4a molecule in Treg-enhanced 
expression of transcription factors such as Foxo1 and Foxo3 to 
help stabilize Foxp3 expression (23). Eos is another transcription 
factor that impacts on the stability of Treg, but this effect could 
be independent of Foxp3 expression (127). Other studies indicate 
that Treg stability involves post translational modification of 
Foxp3 and the induction of its alternative splice variants (128). 
Treg that have enhanced phosphorylated Foxp3 (p-Foxp3) levels 
are more stable as compared to those that have less or no p-Foxp3 
(128–130). Accordingly, phosphatases induced by a highly proin-
flammatory environment could dephosphorylate Foxp3 in Treg, 
which then are converted to become pathogenic Th17 cells (129, 
130). Another study attributed the metabolic state of Th cells to 
their function and phenotype (131). Thus, it was shown that gly-
colysis in Th cells is critical for their conversion to become Treg 
(131). Enolase I, an enzyme, is induced when cell metabolism 
is switched to the glycolytic pathway (131). Enolase I plays an 
essential role by interacting with Foxp3 regulatory sequences to 
effect the expression of an alternative splice variant that utilizes 
exon 2 of Foxp3 (131). However, the mechanisms responsible for 
stability conferred by alternative splice variants of Foxp3 are not 
entirely clear, but could relate to their resistance to degradation 
or the presence of more amino acid residues that can undergo 
phosphorylation.
Some studies have implicated the role of certain microRNAs in 
regulating the stability of Treg (132–134). miRNAs are small oli-
gonucleotides that are expressed endogenously and have critical 
roles in gene expression (132). In general, miRNA 29, 125a, 125b, 
155, and 181 seem to affect differentiation of Th subsets (132). 
Some miRNAs such as miRNA 181 modulates TCR signaling and 
its expression alters with the maturation state of T  cells (135). 
miRNA 155 specifically influences differentiation of Treg and 
Th17 cells which can affect the outcome of inflammatory diseases 
(136, 137).
As differentiation pathways between Treg and Th17 cells are 
shared, these cells exhibit greater tendency for interconversion. 
Some investigators have suggested that TGF-β induced Tregs 
as compared to natural Tregs are more likely to acquire a Th17 
phenotype. Such cells are more likely to express membrane bound 
TGF-β and in an environment enriched in IL-6 or other inflamma-
tory molecules, they become Th17 cells (138). Additionally, TGF-β 
induced cells have not established their complete epigenetic land-
scape and hence are more plastic in nature as compared to natural 
Treg. The conditions where Th17  cells can also become Foxp3 
expressing Treg have not been established as yet, but the Th17 cells 
change to acquire other phenotypes that include Th1, Th2, Tr1, or 
TFH. This could occur because of the relative positioning of Foxp3 
and ROR-γt in a 3-diamensional space in the cell and hence a 
physical interaction may not occur in Th17 cells as does occur in 
Treg (139). For establishing plasticity issues unambiguously, fate-
mapping mice as described in an earlier section are used. Not only 
mice but also human Treg can become Th17 cells when stimulated 
with IL-1β and IL-6 (140). In conclusion, the interconversion of 
Foxp3+ Treg into Th17  cells is appreciable and well established 
upon the change of microenvironment but counterconversion of 
Th17 cells into Foxp3+ Treg cells is not known currently.
CROSS RegULATiON OF TReg AND Th17 
CeLLS DURiNg PATHOPHYSiOLOgY OF 
iNFeCTiOUS DiSeASeS
That Foxp3 is critically involved in the function of Treg has 
been shown in both humans and mice. A spontaneous mutation 
comprising a 2-bp insertion in the coding region of Foxp3 gene 
resulted in a truncated non-functional protein. Mutant mice, 
known as scurfy mice, developed spontaneous multiorgan inflam-
matory lesions (141–143). Male mice exhibited a pronounced 
phenotype as compared to females, suggesting the mutation was 
X-linked. Crossing scurfy mice with Foxp3 transgenics rescued 
the phenotype confirming the role of the mutation in disease 
causation (16). Similarly, patients who had immunodysregula-
tion polyendocrinopathy enteropathy X-linked (IPEX) syndrome 
exhibited a mutation in the Foxp3 gene and developed autoim-
mune enteropathy, psoriasiform or eczematous dermatitis, nail 
dystrophy, and endocrinopathy. IPEX is a rare disease with a 
strong genetic association (144).
The balancing of response in activity of Treg and Th17 cells 
can influence the outcome of numerous infectious and non-
infectious diseases (108). Whether or not these cells play a role 
in orchestrating disease due to infections in non-rodent animals 
is not well established and is suggested based on scanty data, 
which are often unconfirmed. During infections, the dominant 
effect of Treg perhaps is not to dampen protective immunity, but 
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to prevent collateral tissue damage. In some infections, such as 
the one caused by Leishmania, Tregs that were induced de novo 
and recruited to infected sites were specific to pathogen-derived 
antigens (14, 145). Along similar lines, it was demonstrated 
that parasites (Schistosome) and bacteria (Helicobacter pylori, 
Mycobacterium, Histoplasma) promoted the peripheral genera-
tion of Treg (146–148). A protozoan parasite, Toxoplasma gondii, 
caused enhanced immunopathological reactions by inhibiting 
and destabilizing Treg (14, 145). Interestingly, destabilized Treg 
acquired Tbet and produced IFN-γ suggesting their conversion 
into Th1 like cells. In this study, ROR-γt expression by these was 
not analyzed. Tbet controls the expression of TIM-3 and those 
Tregs that express TIM-3 were shown to be resistant to apoptosis 
when ligated with galectin-9 (149). These seemingly contradict-
ing observations could in fact hint the existence of different 
subtypes of Treg some of which will eventually be eliminated 
while some remain in animals and serve as dual function. How 
acute and chronic viral infections signal Treg response has been 
investigated (46). The outcome of acute infections caused by 
viruses such as Friend retrovirus, lymphocytic choriomeningitis 
virus (LCMV), influenza A virus (IAV), West Nile virus (WNV), 
respiratory syncytial virus (RSV), hepatitis A virus (HAV), and 
HSV-1 is influenced to a varying degree by Treg and possible 
Th17 cell responses (150). Acute LCMV infection induced type I 
interferon that diminished Treg function and as a result anti-viral 
CD4+ and CD8+ T cell responses are enhanced (151). Treg also 
critically influence the outcome of infection by IAV, WNV, RSV, 
HAV, and HSV-1 (69). In mice infected with IAV intranasally, 
more Foxp3+ Treg accumulate in the draining mediastinal LNs 
(MLNs) suggesting that virus is able to promote Treg responses 
(152). Mice depleted of Treg developed more severe lesion 
suggesting Tregs were able to control immunopathological 
responses. Respiratory influenza infection induced CCR9+CD4+ 
T helper cell generation in the MLNs. These cells, by responding 
to CCL25, preferentially migrated to the gut and were responsible 
for an inflammatory reaction mediated by Th17 cells (153). The 
antigen specificity and phenotype of migrating CD4+ T cells in 
the gut are not known. Whether or not the migratory cells by 
themselves orchestrated gut inflammation, or induced conver-
sion of resident CD4+ T cells to become Th17 cells, remains to be 
elucidated. However, this study indicated that Th17 cells could 
in fact serve as one of the players of “common mucosal immune 
axis” and could influence the composition of microbiota in the 
gut during some infections (153). Another study demonstrated 
that influenza virus inhibited Th17 mediated control of a second-
ary bacterial infection to cause pneumonia (154). Therefore, 
during IAV pathogenesis, the cross play of Treg and Th17 can 
impact the pathogenesis. During WNV infection in humans, 
Treg helped control the development of clinical symptoms and 
fever by preventing tissue damaging inflammatory reactions 
because asymptomatic individuals had greater numbers of Treg in 
peripheral blood (155). Similarly, WNV infected mice, depleted 
of Treg, developed lethal encephalitis suggesting Treg response 
was protective in nature (155). A specific role of Th17  cells in 
WNV pathogenesis has not been demonstrated, but encephalitis 
caused by WNV was not influenced by the Th17  cell response 
(156). As compared to controls, Treg depleted mice upon RSV 
infection showed enhanced Th2 responses that led to severe 
pulmonary immunopathological lesions (157). Most cases of 
acute HAV infection resolve with efficient viral clearance and 
innocuous pathological consequences, which could relate to how 
Treg are signaled (158). HAV directly binds to its cellular receptor 
1 (HAVCR1 also known as TIM-1) expressed by Treg and as a 
result abrogates their function to promote anti-viral CD8+ T cell 
responses. Efficient CD8+ T cells then help control virus infection 
(159). Whether or not Th17 cells play any role in RSV and HAV 
infection is not clear. The influence of Treg in HSV pathogenesis 
has been extensively studied by numerous approaches (160–164). 
Mice that were depleted of Treg prior to HSV infection mounted 
enhanced primary and memory anti-viral CD8+ T cell responses 
(162) and when Treg were depleted prior to ocular infection 
with HSV-1 heightened CD4+ T cell effector response led to an 
aggravated corneal inflammatory disease, as compared to those 
mice that had intact Treg responses (163). This observation was 
followed up in subsequent studies employing adoptive transfer 
of natural Treg as well as TGF-β induced Treg in mice before 
infection (161, 163). Treg recipient mice developed diminished 
inflammatory lesion as compared to infected controls (161). We 
observed that ligation of CD4+ T  cell expressed sphingosine 1 
phosphate receptor (S1P1) by an agonist FTY720 promoted 
Treg responses (165, 166). These converted cells, however, were 
inclined to acquire a Th17 phenotype when incubated with IL-6 
and exhibited an aggressive proinflammatory activity in HSV-1 
infected animals (165). IL-6 neutralization diminished lesions 
of the disease suggesting that the converted cells might be more 
plastic and in fact more damaging. What stage of infection Treg 
responses are critical in controlling the disease severity was inves-
tigated using a DTR-Foxp3 transgenic mouse model in which 
Treg could be depleted using diphtheria toxin at different times 
post-infection (70). The results suggested that Tregs continue to 
regulate inflammatory responses irrespective of stage when these 
are depleted and that Treg might in fact be acting both in the DLN 
during induction phase of response and at inflammatory sites 
(70). Direct interaction of Treg expressed HVEM and HSV-1-gD 
glycoprotein provided a partial explanation as to how HSV-1 is 
able to signal Treg so promptly after infection (167). The role of 
Th17 cells in HSV-1 induced pathogenesis was also investigated 
using IL-17R KO mice as well as in mice lacking different subunits 
of cytokine IL-23 (p19 and p35), a cytokine critically involved in 
promoting Th17 cell responses (168, 169). These studies demon-
strated that IL-17 contributed by innate immune cells, γδ T cells 
and Th cells, enhanced the severity of inflammatory lesions. 
Th17 cells were predominantly involved during the chronic phase 
of infection, while during the acute phase their contribution was 
minimal (169). This also suggests that inflammatory milieu in 
cornea may induce conversion of some accumulated Treg or 
Th1 cells into a Th17 phenotype. It would be worth investigating 
whether Th17 cells can further become Treg and how would that 
influence the lesion severity.
Most chronic viral infections were shown to influence Treg 
responses and eventually the outcome of chronic infections 
(13, 46). Notably, HIV and HCV are the most prominent chronic 
viral infections where Treg seems to play a critical role in patho-
genesis (13, 46). Precise mechanisms how these infections trigger 
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Treg responses are not clear, but the microenvironments created 
could contribute. HIV, HCV, and IAV could all activate latent 
TGF-β to promote Treg and potentially Th17 responses depend-
ing on its concentration along with that of other inflammatory 
cytokines (43, 170, 171). During HIV infection, Tregs play mul-
tiple roles that range from an early abrogation of effector CD4+ 
T cells to tissue repair during later stages (172). HIV promotes 
Treg responses by modulating the function of DCs which stimu-
late Treg generation (173). Tregs, in turn, control the activation 
of CD4+ T cells to minimize their infection by the virus. Thus, 
activated CD4+ T cells are more susceptible to HIV infection as 
compared to those in resting stage (174). TGF-β produced by 
Treg, and probably other cells, promotes collagen deposition in 
lymphoid organs (175). This poses a problem when the patients 
are given anti-retroviral therapy and immune reconstitution is 
required. Thus, the effective space available would be less for 
immune reconstitution (175). The involvement of Treg in HIV 
pathogenesis, therefore, is a complex issue and needs more study.
Th17 cells seem to play a crucial role in the pathogenesis of 
HIV infection as these cells accumulate abundantly in the gut-
associated lymphoid tissues (GALT) early after infection (176). 
Whether the accumulated Th17  cells in GALT originate from 
Treg or differentiate from naïve cells is still to be established. The 
activated Treg in the gut could contribute to TGF-β production 
and HIV infection could trigger IL-6 production by innate cells. 
Th17  cells are known to express surface CD45RO, CCR5, and 
CXCR4 making them more permissive to HIV infection (177). 
Infected Th17 cells are cleared by the virus itself, or by cytotoxic 
CD8+ T  cells. As Th17  cells are critical for maintaining the 
integrity of mucosal barriers, their depletion could disrupt these 
barriers and initiate generalized immune activation (178, 179). 
The Th17 cells that influence the outcome of HIV infection may 
not necessarily be specific for viral antigens. The role of Th17 cells 
was also demonstrated in long-term non-progressers who exhibit 
pronounced Th17 responses as compared to those who progress 
rapidly to develop HIV-AIDS. Restoration of Th17 cells in patients 
undergoing highly active anti-retroviral therapy is an indicator of 
better prognosis predominantly due to efficient control of bacte-
rial infections by these cells (180). Therefore, a balance of Treg 
and Th17 cell response may critically influence the pathogenesis 
of HIV infection.
HCV and Treg interaction is complicated to investigate, as the 
responses need to be evaluated in the liver, where disease occurs. 
This is particularly confounded by the unavailability of a rodent 
model and the now unavailable chimpanzee being the only reli-
able animal model to study HCV pathogenesis. What determines 
the resolution of infection in only 20% HCV infected patients 
is not clearly understood but is thought to be explained by an 
effective anti-viral CD8+ and CD4+ T cell response (181, 182). In 
those which fail to control infection, some have advocated that an 
induced Treg response, which blunts the activity of effector T cells, 
could be the explanation (183). During HCV infection, the cell 
types that are known to exhibit predominant regulatory activity 
are Tr1 cells and possibly CD8+ Treg in addition to Foxp3 positive 
cells as suggested by some studies (170). However, it remains to 
be evaluated whether Tregs play a beneficial or detrimental role 
during chronic stages of HCV infection. Th17 cells, owing to their 
cytokine secretion, are thought to play a predominant role in the 
repair process leading to fibrosis in the liver and seem not to play 
a critical role early during HCV infection. Accordingly, patients 
treated with interferon and ribavirin therapy had decreased 
Treg responses but minimal effects on Th17 cells were observed 
(183). The Treg and Th17 cell ratio, however, was skewed toward 
Th17  cells with a favorable outcome of therapy. How various 
subsets of Th cells influence HCV pathogenesis remains a con-
troversial issue that merits further evaluation. However, the issue 
is now less relevant since there is a new highly effective anti-viral 
that controls HCV infection.
Regulatory T cells, and to a lesser extent Th17 cells, do influ-
ence the outcome of various infections in pet animals that include 
dogs and cats. These animals also serve as models for various 
infectious and non-infectious diseases. For example, similarities 
in the pathogenesis of feline immunodeficiency virus (FIV) and 
HIV make the cat a useful animal model (184). FIV was shown 
to infect Treg and this made them better suppressors (113, 185). 
FIV infected cats exhibit an early depletion of CD4+ T cells and 
enhanced Treg activity, which in turn compromises anti-viral 
adaptive immunity. This provides the virus an opportunity to 
establish a productive infection (186). More recent reports suggest 
a dysregulation of Treg and Th17 cells during FIV pathogenesis in 
cats during a systemic infection as well as in the placenta leading 
to non-viable pregnancies (113). Whether or not a similar situa-
tion exists in pregnant women infected with HIV is not known.
The canines genome revealed striking similarities in function-
ally related genes with humans and single nucleotide polymor-
phisms have been recently mapped (187). Some shared infections 
between dogs and humans are beginning to provide new insights 
in the pathophysiology of diseases (188). Foxp3+ Treg responses 
have been studied in canine leishmania infection where a variable 
response pattern for Treg and Th17 cells was observed in differ-
ent organs (189). Whether or not interconversion in these cell 
populations occurs during infection is yet to be explained.
The responsiveness of Treg during infectious diseases in 
bovines has been investigated (190–192). Mycobacterium paratu-
berculosis, the causative agent of debilitating Johne’s disease and 
bovine leukemia virus (BLV) induce CD4+ T cells that produced 
IL-10 and those that expressed Foxp3, respectively (190, 192). 
During BLV infections, enhanced Treg responses act to constrain 
anti-viral immunity and probably cause the pathogen to persist 
in animals (191). Johne’s disease is thought to be orchestrated 
by Th1 cells of which some cells also produced IL-17 suggesting 
the plastic nature of these cells. However, as this is mainly a gut 
associated disease, probably the role of balance between Tregs 
and Th17 cells would provide better insights into its pathogenesis.
Small ruminants, such as sheep and goats, serve as major 
livestock for landless laborers and marginal farmers. Which 
cellular mediators are induced early during the response decides 
the efficiency of immunity to infections as well as immunization. 
Major pathogens that infect small ruminants are parasites such 
as Teladorsagia circumcincta and Haemonchus contortus, which 
induce an orchestrated response pattern characterized initially 
by Th1 and during later stages by Th2 and regulatory response 
(193, 194). Whether or not Th17 responses are critical for defense 
against parasitic infections has not been investigated. As these 
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parasites infest gut of these animals, it would be interesting to 
investigate how a balance of Th17 and Treg is affected. Rinderpest 
virus is the only pathogen of animals eliminated from the face of 
earth; however, its close relative pestes des petits ruminantium 
virus (PPRV) is still a major problem in many parts of the 
world in ruminants and cause immunosuppression in the host. 
Both viruses inhibit proliferation of leukocyte in  vitro (195). 
Surprisingly, however, the role of Treg and Th17 during PPRV 
infection or during vaccination against PPRV has not been inves-
tigated and could provide better insights into their pathogenesis 
and eventually better management practices could be employed.
CONCLUSiON
Enumerable studies performed in rodents and to some extent 
in humans exposed to or infected with one or more microbes 
revel an intricate interplay of various subsets of CD4+ T  cells 
which influences the disease outcome. Treg and Th17 response 
dynamics is beginning to provide new insights into the pathogen-
esis of various infections. However, there exist a vast gap in our 
understanding how these cell type are induced, maintained, and 
interact with each other in animals other than inbred rodents. 
Such insights could open new avenues of modifying their func-
tion to achieve better resolution of infection and mitigate tissue 
damaging reaction in humans and animals.
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